Fine-grain analysis of the treatment effect of topiramate on methamphetamine addiction with latent variable analysis

Drug and Alcohol Dependence

Volumn 130, Issue 1-3, 2013, Pages 45-51

  Ma, Jennie Z ^a   Johnson, Bankole A ^b   Yu, Elmer ^c   Weiss, David ^d   McSherry, Frances ^d   Saadvandi, Jim ^e   Iturriaga, Erin ^f   Ait Daoud, Nassima ^b   Rawson, Richard A ^g   Hrymoc, Mark ^g   Campbell, Jan ^h   Gorodetzky, Charles ^h   Haning, William ⁱ   Carlton, Barry ⁱ   Mawhinney, Joseph ^j   Weis, Dennis ^k   McCann, Michael ^l   Pham, Tony ^l   Stock, Christopher ^d   Dickinson, Ruth ^d   Elkashef, Ahmed ^f   Li, Ming D ^b   more..

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

^e Information Management Consultants   (United States)

^f NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

ⁱ Pacific Addiction Research Center   (United States)

^j South Bay Treatment Center   (United States)

^k Lutheran Hospital Office of Research   (United States)

^l Matrix Institute on Addictions   (United States)

more..

Author keywords

Addiction; Latent variable analysis; Methamphetamine; Topiramate

Indexed keywords

PLACEBO; TOPIRAMATE;

ABSTINENCE; ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHAMPHETAMINE DEPENDENCE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STRUCTURAL EQUATION MODELING; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AMPHETAMINE-RELATED DISORDERS; BEHAVIOR, ADDICTIVE; FEMALE; FRUCTOSE; HUMANS; MALE; METHAMPHETAMINE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877093503     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.10.009     Document Type: Article

References (35)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington, DC. 4th ed.
2. Anton R.F., O'Malley S.S., Ciraulo D.A., Cisler R.A., Couper D., Donovan D.M., Gastfriend D.R., Hosking J.D., Johnson B.A., LoCastro J.S., Longabaugh R., Mason B.J., Mattson M.E., Miller W.R., Pettinati H.M., Randall C.L., Swift R., Weiss R.D., Williams L.D., Zweben A. Combined pharmacotherapies and behavioral interventions for alcohol dependence - The COMBINE Study: a randomized controlled trial. JAMA 2006, 295:2003-2017. COMBINE Study Research Group.
3. Cohen J.B., Greenberg R., Uri J., Halpin M., Zweben J.E. Women with methamphetamine dependence: research on etiology and treatment. J. Psychoactive Drugs 2007, Suppl. 4:347-351.
4. Connell A.M., Frye A.A. Growth mixture modelling in developmental psychology: overview and demonstration of heterogeneity in developmental trajectories of adolescent antisocial behaviour. Infant Child Dev. 2006, 15:609-621.
5. Cruickshank C.C., Dyer K.R. A review of the clinical pharmacology of methamphetamine. Addiction 2009, 104:1085-1099.
6. Elkashef A., Kahn R., Yu E., Iturriaga E., Li S.-H., Anderson A., Chiang N., Ait-Daoud N., Weiss D., McSherry F., Serpi T., Rawson R., Hrymoc M., Weis D., McCann M., Pham T., Stock C., Dickinson R., Campbell J., Gorodetzky C., Haning W., Carlton B., Mawhinney J., Li M.D., Johnson B.A. Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction 2012, 107:1297-1306.
7. Fleckenstein A.E., Volz T.J., Riddle E.L., Gibb J.W., Hanson G.R. New insights into the mechanism of action of amphetamines. Annu. Rev. Pharmacol. Toxicol. 2007, 47:681-698.
8. Gueorguieva R., Mallinckrodt C., Krystal J.H. Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses. Arch. Gen. Psychiatry 2011, 68:1227-1237.
9. Hartz D.T., Frederick-Osborne S.L., Galloway G.P. Craving predicts use during treatment for methamphetamine dependence: a prospective, repeated-measures, within-subject analysis. Drug Alcohol Depend. 2001, 63:269-276.
10. Johnson B.A., Ait-Daoud N., Akhtar F.Z., Javors M.A. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Arch. Intern. Med. 2005, 165:1600-1605.
11. Johnson B.A., Ait-Daoud N., Bowden C.L., DiClemente C.C., Roache J.D., Lawson K., Javors M.A., Ma J.Z. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003, 361:1677-1685.
12. Johnson B.A., Ait-Daoud N., Seneviratne C., Roache J.D., Javors M.A., Wang X.-Q., Liu L., Penberthy J.K., DiClemente C.C., Li M.D. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am. J. Psychiatry 2011, 168:265-275.
13. Johnson B.A., Roache J.D., Ait-Daoud N., Wells L.T., Wallace C.L., Dawes M.A., Liu L., Wang X.-Q. Effects of acute topiramate dosing on methamphetamine-induced subjective mood. Int. J. Neuropsychopharmacol. 2007, 10:85-98.
14. Johnson B.A., Rosenthal N., Capece J.A., Wiegand F., Mao L., Beyers K., McKay A., Ait-Daoud N., Anton R.F., Ciraulo D.A., Kranzler H.R., Mann K., O'Malley S.S., Swift R.M., Topiramate for Alcoholism Advisory Board, Topiramate for Alcoholism Study Group Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007, 298:1641-1651.
15. Kampman K.M., Pettinati H., Lynch K.G., Dackis C., Sparkman T., Weigley C., O'Brien C.P. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. 2004, 75:233-240.
16. Kaye S., McKetin R., Duflou J., Darke S. Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction 2007, 102:1204-1211.
17. Keel P.K., Fichter M., Quadflieg N., Bulik C.M., Baxter M.G., Thornton L., Halmi K.A., Kaplan A.S., Strober M., Woodside D.B., Crow S.J., Mitchell J.E., Rotondo A., Mauri M., Cassano G., Treasure J., Goldman D., Berrettini W.H., Kaye W.H. Application of a latent class analysis to empirically define eating disorder phenotypes. Arch. Gen. Psychiatry 2004, 61:192-200.
18. Klee H. A new target for behavioural research - amphetamine misuse. Br. J. Addict. 1992, 87:439-446.
19. Kuczenski R. Biochemical actions of amphetamine and other stimulants. Stimulants, Neurochemical, Behavioral, and Clinical Perspectives. 1983, 31-61. Raven Press, New York. I. Creese (Ed.).
20. Leombruni P., Lavagnino L., Fassino S. Treatment of obese patients with binge eating disorder using topiramate: a review. Neuropsychiatr. Dis. Treat. 2009, 5:385-392.
21. Ling W., Shoptaw S. Integration of research in pharmacotherapy for addictive disease: where are we? Where are we going?. J. Addict. Dis. 1997, 16:83-102.
22. Ma J.Z., Ait-Daoud N., Johnson B.A. Topiramate reduces the harm of excessive drinking: implications for public health and primary care. Addiction 2006, 101:1561-1568.
23. McCutcheon A.L. Latent Class Analysis 1987, Sage Publications, Thousand Oaks, CA.
24. Muthén B., Brown C.H., Masyn K., Jo B., Khoo S.T., Yang C.C., Wang C.P., Kellam S.G., Carlin J.B., Liao J. General growth mixture modeling for randomized preventive interventions. Biostatistics 2002, 3:459-475.
25. Muthén B., Brown H.C. Estimating drug effects in the presence of placebo response: causal inference using growth mixture modeling. Stat. Med. 2009, 28:3363-3385.
26. Muthén B., Brown H.C., Hunter A.M., Cook I.A., Leuchter A.F. General approaches to analysis of course: applying growth mixture modeling to randomized trials of depression medication. Causality and Psychopathology: Finding the Determinants of Disorders and Their Cures 2011, 159-178. Oxford University Press, New York. P.E. Shrout, K.M. Keyes, K. Ornstein (Eds.).
27. Muthén B., Shedden K. Finite mixture modeling with mixture outcomes using the EM algorithm. Biometrics 1999, 55:463-469.
28. Muthén L.K., Muthén B.O. Mplus User's Guide 1998-2010, Muthén & Muthén, Los Angeles, CA. sixth ed.
29. Shoptaw S., Huber A., Peck J., Yang X., Liu J., Dang J., Roll J., Shapiro B., Rotheram-Fuller E., Ling W. Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006, 85:12-18.
30. Srisurapanont M., Jarusuraisin N., Kittirattanapaiboon P. Treatment for amphetamine dependence and abuse. Cochrane Database Syst. Rev. 2001, 4:CD003022.
31. Stanger C. Latent growth mixture models: an important new tool for developmental researchers. Infant Child Dev. 2006, 15:635-637.
32. Suwaki H. Methamphetamine abuse in Japan. NIDA Res. Monogr. 1991, 115:84-98.
33. U.S.Department of Health and Human Services National Survey on Drug Use and Health: The NSDUH Report. Methamphetamine Use 2007, Office of Applied Studies, Substance Abuse and Mental Health Services Administration. http://www.oas.samhsa.gov/2k7/meth/meth.htm.
34. Wu L.T., Blazer D.G., Patkar A.A., Stitzer M.L., Wakim P.G., Brooner R.K. Heterogeneity of stimulant dependence: a national drug abuse treatment clinical trials network study. Am. J. Addict. 2009, 18:206-218.
35. Zullino D.F., Cottier A.C., Besson J. Topiramate in opiate withdrawal. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26:1221-1223.